|
PACE- MI Registry Study
Summary
The aim of this registry study is to address important public health question whether post-MI survival is impacted by beta-blocker dose. This multicenter registry study will provide invaluable information regarding practice patterns and efficacy of treatment in real-world settings versus those that exist in the controlled setting of randomized clinical trial.
Description
This is a NIH funded, NHLB sponsored non-voluntary registry of consecutive patients diagnosed as having a MI at the study site. Baseline demographic, hospitalization and use of beta-blockers at 24 hours post MI through hospital discharge information will be captured and recorded via an electronic data capture system. Follow-up information requiring informed consent prior to discharge (vital status, beta-blocker use, other cardiac medications and any cardiovascular hospitalization) will be obtained at 1 year and 2 year post MI via phone contact or medical chart review.
Inclusion/exclusion
1. Consecutive patients admitted with a myocardial infarctiondocumented by both of the following: a. cardiac enzymes (CPK elevation > two times or troponinelevation > three times the upper limit of normal for thelab) b. Electrocardiographic changes and/or symptomsconsistent with myocardial infarction (i.e. chest pain, shortness of breath)
Principal Investigator
Joseph Germano, D.O.
Department
Division of Cardiology
Email
jgermano@winthrop.org
Other Contact
Wendy Drewes, RN,BSN wdrewes@winthrop.org 516-663-2929
|
